Short Summary
Medela and M.E.A.C. Engineering have settled their dispute over U.S. Patent 8,858,534 and jointly moved to terminate the pending inter partes review. The Board has not yet instituted the IPR, and the parties seek confidentiality for the settlement agreement.
Detailed Summary
In IPR2024-01076 concerning U.S. Patent 8,858,534 B2, petitioners Medela LLC and Medela AG and patent owner M.E.A.C. Engineering Ltd. have reached a settlement that resolves all outstanding issues. The parties filed a joint motion to terminate the inter partes review under 35 U.S.C. § 317(a), citing the lack of an institution decision and the desire to preserve resources. They also request that the settlement be treated as business‑confidential information and kept separate from the patent file. No claims were instituted, and the proceeding ends without a merit determination.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Medela LLC et al. vs M.E.A.C. Engineering Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Biofrontera Incorporated et al.vsSun Pharmaceutical Industries, Inc.
The PTAB found all challenged claims unpatentable by a preponderance of the evidence. The Petitioner successfully argued that combining prior art references (Lundahl and Larsen) rendered the illuminator system obvious to a Person Having Ordinary Skill in the Art (POSITA).
Samsung Electronics Co. Ltd. et al.vsMobile Data Technologies LLC
Samsung has filed an IPR petition challenging Mobile Data Technologies’ U.S. Patent 8,825,801, asserting that the claims are obvious over two prior‑art combinations (Randall‑Forsyth and Pelkey‑Eck) and urging the Board to institute the review.
Regions BankvsUnited Services Automobile Association
Regions Bank and USAA settled their inter partes review dispute over USAA's automobile insurance patent, leading the PTAB to terminate the proceeding without a final written decision.
Samsung Electronics Co. Ltd. et al.vsMaxell, Ltd.
Maxell’s preliminary response urges the PTAB to deny Samsung’s IPR petition, contending that the prior art never teaches the claimed ‘unlock’ function and that Samsung’s expert testimony is conclusory.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim. All 15 claims are now under review.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.